Innate immunity and myocardial adaptation to ischemia

Basic Research in Cardiology

Volumn 104, Issue 1, 2009, Pages 22-32

  Valeur, Hanne Støre ^a   Valen, Guro ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Adaptive immunity; Cytokines; Nuclear factor kappa B; Preconditioning; Toll like receptors

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLUENZA VACCINE; LIGAND; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR;

ACUTE HEART INFARCTION; ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ATHEROSCLEROSIS; AUTOCRINE EFFECT; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DAMAGE; CELL DEATH; CELL PROTECTION; CELL STRESS; CELL STRUCTURE; CELLULAR IMMUNITY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DENDRITIC CELL; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; GENE CONTROL; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMORAL IMMUNITY; HYPEROXIA; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION PREVENTION; INFLAMMATION; INFLUENZA; INNATE IMMUNITY; ISCHEMIC PRECONDITIONING; LIMB ISCHEMIA; NONHUMAN; OXIDATION REDUCTION REACTION; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ACCLIMATIZATION; HEART; HUMANS; IMMUNITY, INNATE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MODELS, CARDIOVASCULAR; MYELOID DIFFERENTIATION FACTOR 88; MYOCARDIAL ISCHEMIA; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57949097756     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-008-0756-6     Document Type: Review

References (84)

1. Akira S, Takeda K (2004) Toll-like receptor signaling. Nat Rev Immunol 4:499-511
2. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2:675-680
3. Aukrust P, Damøs JK, Gullestad L (2003) Immunomodulating therapy: new treatment modality in congestive heart failure. Congest Heart Fail 9:64-69
4. Belesjorow S, Bolle I, Duschin A, Heusch G, Schulz R (2003) TNF-α antibodies are as effective as ischemic preconditioning in reducing infarct size in rabbits. Am J Physiol 284:H927-H930
5. Bigdeli MR, Khoshbaten A (2008) In vivo preconditioning with normobaric hyperoxia induces ischemic tolerance partly by triggering tumor necrosis factor a-converting enzyme/tumor necrosis factor-a/nuclear factor kappa B. Neuroscience 153:671-678
6. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR (2006) Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 72:384-393
7. Brown JM, Grosso MA, Terada LS, Whitman GJ, Banerjee A, White CW, Harken AH, Repine JE (1989) Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci 86:2516-2520
8. Chandrasekar B, Freeman GL (1997) Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium. FEBS Lett 401:30-34
9. Chao W, Shen Y, Zhu X, Zhao H, Novikov M, Schmidt U, Rosenzweig A (2005) Lipopolysaccharide improve cardiomyocyte survival and function after serum deprivation. J Biol Chem 280:21997-22005
10. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED (2004) Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 128:170-179
11. Dana A, Jonassen AK, Yamashita N, Yellon DM (2000) Adenosine A(1) receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase. Circulation 101:2841-2848
12. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, Bolli R (2004) IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX2. Cardiovasc Res 64:61-71
13. Deuchar GA, Opie LH, Lecour S (2007) TNFa is required to confer protection in an in vivo model of clasical ischemic preconditioning. Life Sci 80:1686-1691
14. Favre J, Musette P, Douin-Echinard V, Laude K, Henry JP, Arnal JF, Thuillez C, Richard V (2007) Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 27:1064-1071
15. Fischer P, Hilfiker-Kleiner D (2007) Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis. Basic Res Cardiol 102:279-297
16. Fox IS (1996) The immune system. In: Fox IS (ed) Human physiology. WC Brown Publishers, pp 424-456
17. Frantz S, Ertl G, Bauersachs J (2007) Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 4:444-454
18. Frantz S, Kelly RA, Bourcier T (2001) Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem 276:5197-5203
19. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA (1999) Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104:271-280
20. Girn HRS, Ahilathirunayagam S, Mavor AID, Homer-Vanniasinkam S (2007) Reperfusion syndrome: Cellular mechanisms of microvascular dysfunction and potential therapeutic strategies. Vasc Endovascular Surg 41:277-293
21. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD (1996) Myocardial protection by brief ischemia in noncardiac tissue. Circulation 94:2193-2200
22. Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, Wu WJ, Han H, Laubach VE, Ping P, Yang Z, Qiu Y, Bolli R (1999) The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci 96:11507-11512
23. Gurantz D, Yndestad A, Halvorsen B, Lunde OV, Omens JH, Ueland T, Aukrust P, Moore CD, Kjekshus J, Greenberg BH (2005) Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling. Cardiovasc Res 67:106-115
24. Gurfinkel EP, de la Fuente RL (2004) Two-year follow-up of the FLU vaccination acute coronary syndromes (FLUVACS) registry. Texas Haert Inst J 31:28-32
25. Gurfinkel EP, de la Fuente LR, Mendiz O, Mautner B (2004) Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur Heart J 25:25-31
26. Hall G, Hasday JD, Rogers TB (2006) Regulating the regulator: NF-kappaB signaling in the heart. J Mol Cell Cardiol 41:580-591
27. Hayden MS, West AP, Ghosh S (2006) NF-kappaB and the immune response. Oncogene 25:6758-6780
28. Hiasa G, Hamada M, Ikeda S, Hiwada K (2001) Ischemic preconditioning and lipopolysaccharide attenuate nuclear factor kappa B activation and gene expression of inflammatory cytokines in the ischemia-reperfused myocardium. Jpn Circ J 65:984-990
29. Jones WK, Brown M, Wilhide M, He S, Ren X (2005) NF-kappaB in cardiovascular disease: Diverse and specific effects of a "general" transcription factor? Cardiovasc Toxicol 5:183-202
30. Karikó K, Weissman D, Welsh FA (2004) Inhibition of toll-like receptor and cytokine signaling - a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab 24:1288-1304
31. Kim SC, Ghanem A, Stapel H (2007) Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol 7:5-9
32. Knuefermann P, Sakata Y, Baker JS, Huang CH, Sekiguchi K, Hardarson HS, Takeuchi O, Akira S, Vallejo JG (2004) Toll-like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart. Circulation 110:3693-3698
33. Kurdi M, Booz GW (2007) Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signalling. J Cardiovasc Pharmacol 50:126-141
34. Labruto F, Yang J, Vaage J, Valen G (2005) Role of tumor necrosis factor alpha and its receptor 1 in preconditioning by hyperoxia. Basic Res Cardiol 100:198-207
35. 12 myotubes. Life Sci 79:2194-2201
36. Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, Opie LH (2005) Pharmacological preconditioning with tumor necrosis factor 1 alpha activates signal transducer and activator of transcription-3 without involving classic prosurvival kinases. Circulation 112:3911-3118
37. Li C, Browder W, Kao RL (1999) Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart. Am J Physiol 276:H543-H552
38. Li C, Kao RL, Ha T, Kelley J, Browder IW, Williams DL (2001) Early activation of IKKbeta during in vivo myocardial ischemia. Am J Physiol 280:H1264-H1271
39. Li G, Labruto F, Sirsjö A, Chen F, Vaage J, Valen G (2004) Myocardial protection by remote preconditioning: The role of nuclear factor kappa B p105 and inducible nitric oxide synthase. Eur J Cardiothorac Surg 26:968-973
40. Liem DA, Honda HM, Zhang J, Woo D, Ping P (2007) Past and present course of cardioprotection against ischemia-reperfusion injury. J Appl Physiol 103:2129-2136
41. Ma S, Xiang J, Wu J, Hu B (2003) Effects of lipoteichoic acid induced delayed preconditioning on ischemia-reperfusion injury in isolated rat hearts. Huazhong Univ Sci Technol Med Sci 23:230-233
42. Matzinger P (2002) The danger model: A renewed sense of self. Science 296:301-305
43. Maulik N, Sato M, Price BD, Das DK (1998) An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett 429:365-369
44. Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1:135-145
45. Meyers DG (2003) Myocardial infarction, stroke, and sudden cardiac death may be prevented by influenza vaccination. Curr Atheroscler Rep 5:146-149
46. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, Young LH (2008) Macrophage migration inhibitory factor stimulates AMP-activated protein kinas in the ischemic heart. Nature 451:578-583
47. Mitchell JA, Paul-Clarke MJ, Clarke GW, McMaster SM, Cartwright N (2007) Critical role of toll-like receptors and nucleotide oligomerization domain in the regulation of health and disease. J Endocrinol 193:323-330
48. Morand EF (2005) New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 35:419-426
49. Morgan EN, Boyle EM Jr, Yun W, Griscavage-Ennis JM, Farr AL, Canty TG Jr, Pohlman TH, Verrier ED (1999) An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann Thorac Surg 68:377-382
50. Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136
51. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W (2000) Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 102:3039-3045
52. Neckar J, Ostadal B, Kolar F (2004) Myocardial infarct size limiting effect of chronic hypoxia persists for five weeks of normoxic recovery. Physiol Res 53:621-628
53. Nemeto S, Vallejo JG, Knuefermann P, Misra A, Defreitas G, Carabello BA, Mann DL (2002) Escherichia coli LPS-induced LV dysfunction: Role of toll-like receptor 4 in the adult heart. Am J Physiol 282:H2361-H2323
54. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M (2003) Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. New Engl J Med 348:1322-1332
55. Nilsson J, Hansson GK, Shah PK (2005) Immunomodulation of atherosclerosis: Implications for vaccine development. AT&VB 25:18-28
56. Otani H (2008) Ischemic preconditioning: From molecular mechanisms to therapeutic opportunities. Antiox Redox Signal 10:207-247
57. Oxman T, Arad M, Klein R, Avazov N, Rabinowitz B (1997) Limb ischemia preconditions the heart against reperfusion tachyarrhythmia. Am J Physiol 273:H1707-H1712
58. Oyama J, Blais C, Liu X, Pu M, Kobzik L, Kelley RA, Bourcier T (2004) Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109:784-789
59. Sack MN (2002) Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease. Pharmacol Ther 94:123-135
60. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR (2006) Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 177:1272-1281
61. Schulz R, Aker S, Belosjorov S, Heusch G (2004) TNFα in ischemia/ reperfusion injury and heart failure. Basic Res Cardiol 99:8-11
62. Shi Y, Evans JE, Rode KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516-521
63. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, Bolli R (2000) Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci 97:10197-10202
64. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M, Takeuchi O, Akira S, Takeishi Y, Kubota I (2003) Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108:2905-2910
65. Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ (2006) IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res 69:164-177
66. Smith RM, Suleman N, McCarthy J, Sack MN (2002) Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFα gene. Cardiovasc Res 55:553-560
67. Song W, Furman BL, Parratt JR (1998) Monophosphoryl lipid A reduces both arrhythmia severity and infarct size in a rat model of ischaemia. Eur J Pharmacol 345:285-287
68. Suleman N, Somers S, Smith R, Opie LH, Lecour S (2008) Dual activation of STAT-3 and Akt is required during the trigger phase of ischemic preconditioning. Cardiovasc Res 79:127-133
69. Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, Inubushi T, Kinoshita M (1999) Renal ischemia/reperfusion remotely improves myocardial energy metabolism during myocardial ischemia via adenosine receptors in rabbits: Effects of remote preconditioning. J Am Coll Cardiol 100:559-563
70. Takeda K, Akira S (2004) TLR signaling pathways. Semin Immunol 16:3-9
71. Teoh N, Field J, Farrell G (2006) Interleukin 6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischemic preconditioning in mice. J Hepatol 45:20-27
72. Tissier R, Berdeaux A, Ghaleh B, Couvreur N, Krieg T, Cohen MV, Downey J (2008) Making the heart resistant to infarction: How can we further decrease infarct size? Front Biosci 13:284-301
73. Tsan MF, Gao B (2004) Endogenous ligands of toll-like receptors. J Leukoc Biol 76:514-519
74. Tähepãld P, Vaage J, Starkopf J, Valen G (2003) Hyperoxia elicits myocardial protection through a nuclear factor kappaB-dependent mechanism in the rat heart. J Thorac Cardiovasc Surg 125:650-660
75. Valen G, Hansson GK, Dumitrescu A, Vaage J (2000) Unstable angina activates myocardial heat shock protein 72, endothelial nitric oxide synthase, and transcription factors NFkB and AP-1. Cardiovasc Res 47:49-56
76. Valen G, Yan ZQ, Hansson GK (2001) Nuclear factor kappa-B and the heart. J Am Coll Cardiol 38:307-314
77. Wallin RP, Lundqvist A, Moré SH, von Bonin A, Kiessling R, Ljunggren HG (2002) Heat-shock proteins as activators of the innate immune system. Trends Immunol 23:130-135
78. Wang Y, Yin BL, Liu S, Xue S (2007) Cardioprotective effect by tumor necrosis factor-a and interleukin-6 through late preconditoning in unstable angina patients. Arch Med Res 38:80-85
79. Xuan YT, Tang XL, Banerjee S, Takano H, Li RC, Han H, Qiu Y, Li JJ, Bolli R (1999) Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 84:1095-1109
80. Yan ZQ, Hansson GK (2007) Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 219:187-203
81. Yellon DK, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121-1123
82. Zacharowski K, Frank S, Otto M, Chatterjee PK, Cuzzocrea S, Hafner G, Pfeilschifter J, Thiemermann C (2000) Lipoteichoic acid induces delayed protection in the rat heart: A comparison with endotoxin. Arterioscler Thromb Vasc Biol 20:1521-1528
83. Zhang C (2008) The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 103:398-406
84. Zhao ZQ, Vinten-Johansen J (2006) Postconditioning: Reduction of reperfusion-induced injury. Cardiovasc Res 70:200-211